Compare APLE & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLE | DYN |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2007 | 2020 |
| Metric | APLE | DYN |
|---|---|---|
| Price | $13.40 | $17.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $13.00 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 3.9M | 1.7M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,238,622,000.00 | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | $2.35 | N/A |
| P/E Ratio | $18.22 | ★ N/A |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $10.85 | $8.25 |
| 52 Week High | $13.57 | $25.00 |
| Indicator | APLE | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 74.69 | 41.97 |
| Support Level | $11.43 | $16.47 |
| Resistance Level | N/A | $19.65 |
| Average True Range (ATR) | 0.25 | 0.98 |
| MACD | 0.06 | -0.30 |
| Stochastic Oscillator | 83.27 | 5.45 |
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.